Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

Consistency of initial antiretroviral therapy with HIV treatment guidelines in a US cohort of HIV-infected women.

Cocohoba J, Wang QJ, Cox C, Gange SJ, Cohen M, Glesby M, DeHovitz JA, Greenblatt RM.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):377-83. doi: 10.1097/QAI.0b013e318160d552.

PMID:
18176324
2.

Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.

Golub ET, Benning L, Sharma A, Gandhi M, Cohen MH, Young M, Gange SJ.

Clin Infect Dis. 2008 Jan 15;46(2):305-12. doi: 10.1086/524752.

PMID:
18171267
3.

Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus.

Ahdieh L, Gange SJ, Greenblatt R, Minkoff H, Anastos K, Young M, Nowicki M, Kovacs A, Cohen M, Muñoz A.

Am J Epidemiol. 2000 Nov 15;152(10):923-33.

PMID:
11092434
4.

Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study.

Berhane K, Karim R, Cohen MH, Masri-Lavine L, Young M, Anastos K, Augenbraun M, Watts DH, Levine AM.

J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1245-52.

PMID:
15385731
5.

Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels.

Ahdieh Grant L, Silverberg MJ, Palacio H, Minkoff H, Anastos K, Young MA, Nowicki M, Kovacs A, Cohen M, Muñoz A.

AIDS. 2001 Nov 9;15(16):2101-8.

PMID:
11684929
6.

Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.

Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M.

AIDS. 2007 May 11;21(8):939-46.

PMID:
17457087
7.

Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.

Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA, Kempf MC.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):553-8. doi: 10.1097/QAI.0b013e31816856c5.

PMID:
18285713
8.

Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians.

Mekonnen Y, Dukers NH, Sanders E, Dorigo W, Wolday D, Schaap A, Geskus RB, Coutinho RA, Fontanet A.

Ethiop Med J. 2003 Jun;41 Suppl 1:61-5.

PMID:
15227882
9.

Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1-infected US veterans (1992-2004).

Holodniy M, Hornberger J, Rapoport D, Robertus K, MaCurdy TE, Lopez J, Volberding P, Deyton L.

J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):20-9.

PMID:
17091020
10.

The relationship between antiretroviral prescription patterns and treatment guidelines in treatment-naïve HIV-1-infected patients.

Suarez-Lozano I, Viciana P, Lacalle JR, Teira R, Lozano F, Lopez-Aldeguer J, Pedrol E, Domingo P, Cosin J, Roca B, Geijo P, Fuente B, Vergara A, Ribera E, Galindo MJ, Zapata A, Sanchez T, Vidal F, Munoz-Sanz A, Munoz-Sanchez J, Garrido M.

HIV Med. 2009 Oct;10(9):573-9. doi: 10.1111/j.1468-1293.2009.00731.x.

11.

National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines?

Beck EJ, Vitoria M, Mandalia S, Crowley S, Gilks CF, Souteyrand Y.

AIDS. 2006 Jul 13;20(11):1497-502.

PMID:
16847404
12.

Efficacy and tolerability of initial antiretroviral therapy: a systematic review.

Carr A, Amin J.

AIDS. 2009 Jan 28;23(3):343-53; discussion 355-6. doi: 10.1097/QAD.0b013e32831db232. Review.

PMID:
19114855
13.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
14.

Herpes zoster in women with and at risk for HIV: data from the Women's Interagency HIV Study.

Glesby MJ, Hoover DR, Tan T, Shi Q, Gao W, French AL, Maurer T, Young M, Dehovitz J, Ru J, Anastos K.

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1604-9.

PMID:
15577417
15.

Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study.

Kirstein LM, Greenblatt RM, Anastos K, Levine A, French AL, Minkoff H, Silver S, Gange SJ; Women's Interagency HIV Study Collaborative Research Group.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):495-503.

PMID:
11981366
16.

Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians.

Mekonnen Y, Dukers NH, Sanders E, Dorigo W, Wolday D, Schaap A, Geskus RB, Coutinho RA, Fontanet A.

AIDS. 2003 Apr 11;17(6):815-9.

PMID:
12660528
17.

Adult clinical and immunologic outcomes of the national antiretroviral treatment program in Rwanda during 2004-2005.

Lowrance DW, Ndamage F, Kayirangwa E, Ndagije F, Lo W, Hoover DR, Hanson J, Elul B, Ayaba A, Ellerbrock T, Rukundo A, Shumbusho F, Nash D, Mugabo J, Assimwe A.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):49-55. doi: 10.1097/QAI.0b013e3181b03316.

PMID:
19617847
18.

Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.

Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.

Antivir Ther. 2009;14(3):339-47.

PMID:
19474468
19.

A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?

Simcock M, Sendi P, Ledergerber B, Keller T, Schüpbach J, Battegay M, Günthard HF; Swiss HIV Cohort Study.

Antivir Ther. 2006;11(3):305-14.

PMID:
16759046
20.

Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy.

Brumme ZL, Brumme CJ, Chui C, Mo T, Wynhoven B, Woods CK, Henrick BM, Hogg RS, Montaner JS, Harrigan PR.

J Infect Dis. 2007 Jun 1;195(11):1694-704. Epub 2007 Apr 24.

PMID:
17471440

Supplemental Content

Support Center